63.29
0.87%
0.7392
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Disc Medicine Inc Borsa (IRON) Ultime notizie
Victory Capital Management Inc. Has $10.81 Million Stock Position in Disc Medicine, Inc. (NASDAQ:IRON) - MarketBeat
Disc Medicine secures $200m financing to support trials - MSN
Contrasting Pharming Group (OTCMKTS:PHGUF) and Disc Medicine (NASDAQ:IRON) - Defense World
Disc Medicine chief medical officer sells $546,152 in stock - Investing.com
Disc Medicine chief medical officer sells $546,152 in stock By Investing.com - Investing.com UK
Disc Medicine Announces New Equity Sales Agreement - TipRanks
FY2024 EPS Estimates for Disc Medicine Raised by Analyst - MarketBeat
Wedbush Forecasts Disc Medicine's Q4 Earnings (NASDAQ:IRON) - MarketBeat
Disc Medicine FY2024 EPS Estimate Raised by Leerink Partnrs - MarketBeat
Lifesci Capital Predicts Stronger Earnings for Disc Medicine - MarketBeat
Disc Medicine FY2024 EPS Forecast Boosted by HC Wainwright - MarketBeat
Paradigm Biocapital Advisors LP Adjusts Stake in Disc Medicine I - GuruFocus.com
Analysts Set Disc Medicine, Inc. (NASDAQ:IRON) PT at $85.80 - MarketBeat
FY2028 Earnings Forecast for Disc Medicine Issued By Wedbush - MarketBeat
Disc Medicine Reports Q3 2024 Results and Strategic Progress - TipRanks
Disc Medicine (NASDAQ:IRON) Announces Quarterly Earnings Results - MarketBeat
Disc Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Disc Medicine stock gets price target bump from H.C. Wainwright, Buy rating intact - Investing.com UK
Disc Medicine (IRON) to Present at Major Healthcare Investor Conferences | IRON Stock News - StockTitan
Learn to Evaluate (IRON) using the Charts - Stock Traders Daily
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Disc Medicine Secures $200M Financing, Reports FDA Fast-Track Potential for Key Drug | IRON Stock News - StockTitan
Disc Medicine Inc. (IRON) Quarterly 10-Q Report - Quartzy
Disc Medicine secures $200M in debt financing from Hercules Capital - MSN
Scotiabank Boosts Disc Medicine (NASDAQ:IRON) Price Target to $70.00 - Defense World
Wellington Management Group LLP Increases Stake in Disc Medicine Inc - GuruFocus.com
Disc Medicine Leaps on Investment - Baystreet.ca
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital - citybiz
Disc Medicine Secures $200 Million in Financing - citybiz
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. - The Manila Times
Disc Medicine Secures Massive $200M Financing Deal to Advance Clinical Pipeline | IRON Stock News - StockTitan
FY2024 Earnings Forecast for Disc Medicine Issued By Wedbush - Defense World
Leerink Partnrs Forecasts Weaker Earnings for Disc Medicine - MarketBeat
Disc Medicine (NASDAQ:IRON) Stock Rating Upgraded by Raymond James - Defense World
FY2024 Earnings Estimate for Disc Medicine Issued By Wedbush - MarketBeat
Disc Medicine Announces Multiple Presentations Across - GlobeNewswire
Disc Medicine (IRON) Rally Strengthens With After-Hour Gains On Positive Clinical Milestone - Stocks Telegraph
Disc medicine director sells $427,525 in stock By Investing.com - Investing.com South Africa
Disc medicine director sells $427,525 in stock - Investing.com
Disc Medicine (NASDAQ:IRON) Stock Price Up 7%Here's Why - MarketBeat
HC Wainwright Reaffirms Buy Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Scotiabank upgrades Disc Medicine shares target on trial update By Investing.com - Investing.com UK
Disc Medicine to Present Complete DISC-0974 Trial Data, Portfolio Updates at ASH 2024 | IRON Stock News - StockTitan
Disc Medicine stock target upgraded on bitopertin prospects By Investing.com - Investing.com Canada
Disc Medicine (NASDAQ:IRON) Upgraded at Morgan Stanley - MarketBeat
FDA aligns with Disc Medicine on EPP treatment study - Investing.com India
Wedbush Reaffirms Outperform Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Disc over the moon as FDA urges Apollo bid with bitopertin in EPP - BioWorld Online
FDA aligns with Disc Medicine on EPP treatment study By Investing.com - Investing.com Canada
Disc Medicine stock rallies 26% on FDA update for bitopertin (update) - Seeking Alpha
Disc Medicine Shares Rise After Positive Feedback From FDA - Marketscreener.com
Disc Medicine (NASDAQ:IRON) Shares Gap UpTime to Buy? - MarketBeat
Disc Medicine leaps as it gets positive FDA feedback - The Pharma Letter
Raymond James increases Disc Medicine shares to Strong Buy on new drug - Investing.com UK
Disc Medicine (NASDAQ:IRON) Upgraded to Strong-Buy at Raymond James - MarketBeat
Disc Medicine Gains FDA Support for Bitopertin Trial - TipRanks
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval - The Manila Times
Disc Medicine Announces Successful End of Phase 2 Meeting - GlobeNewswire
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):